{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:28:30Z","timestamp":1786980510279,"version":"build-2736575974"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,3,23]],"date-time":"2019-03-23T00:00:00Z","timestamp":1553299200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s10096-019-03533-y","type":"journal-article","created":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T20:05:34Z","timestamp":1553285134000},"page":"819-827","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["New antimicrobial options for the management of complicated intra-abdominal infections"],"prefix":"10.1007","volume":"38","author":[{"given":"Sebastiano","family":"Leone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Damiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Pezone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly E.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cascella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniello","family":"Alfieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Pace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,23]]},"reference":[{"key":"3533_CR1","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1080\/14787210.2017.1372750","volume":"15","author":"P Montravers","year":"2017","unstructured":"Montravers P, Tashk P, Tran Dinh A (2017) Unmet needs in the management of intra-abdominal infections. Expert Rev Anti-Infect Ther 15:839\u2013850","journal-title":"Expert Rev Anti-Infect Ther"},{"issue":"Suppl 1","key":"3533_CR2","first-page":"S46","volume":"16","author":"S Esposito","year":"2008","unstructured":"Esposito S, Carosi G, Leone S (2008) Current guidelines for the treatment of intra-abdominal infections. Infez Med 16(Suppl 1):S46\u2013S52","journal-title":"Infez Med"},{"key":"3533_CR3","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.idc.2009.04.007","volume":"23","author":"JS Solomkin","year":"2009","unstructured":"Solomkin JS, Mazuski J (2009) Intra-abdominal sepsis: newer interventional and antimicrobial therapies. Infect Dis Clin N Am 23:593\u2013608","journal-title":"Infect Dis Clin N Am"},{"key":"3533_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1086\/649554","volume":"50","author":"JS Solomkin","year":"2010","unstructured":"Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, O'Neill PJ, Chow AW, Dellinger EP, Eachempati SR, Gorbach S, Hilfiker M, May AK, Nathens AB, Sawyer RG, Bartlett JG (2010) Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the surgical infection society and the Infectious Diseases Society of America. Clin Infect Dis 50:133\u2013164","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"3533_CR5","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1179\/joc.2009.21.Supplement-1.30","volume":"21","author":"S Esposito","year":"2009","unstructured":"Esposito S, Leone S, Carosi G (2009) Analysis of current guidelines for intra-abdominal infections. J Chemother 21(Suppl 1):S30\u2013S35","journal-title":"J Chemother"},{"key":"3533_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2165\/11599800-000000000-00000","volume":"72","author":"S Blot","year":"2012","unstructured":"Blot S, De Waele JJ, Vogelaers D (2012) Essentials for selecting antimicrobial therapy for intra-abdominal infections. Drugs 72:17\u201332","journal-title":"Drugs"},{"key":"3533_CR7","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ijantimicag.2015.12.021","volume":"47","author":"LS Syue","year":"2016","unstructured":"Syue LS, Chen YH, Ko WC, Hsueh PR (2016) New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance. Int J Antimicrob Agents 47:250\u2013258","journal-title":"Int J Antimicrob Agents"},{"key":"3533_CR8","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s40265-015-0506-7","volume":"75","author":"YR Lee","year":"2015","unstructured":"Lee YR, McMahan D, McCall C, Perry GK (2015) Complicated intra-abdominal infections: the old antimicrobials and the new players. Drugs 75:2097\u20132117","journal-title":"Drugs"},{"key":"3533_CR9","doi-asserted-by":"publisher","first-page":"e2015040","DOI":"10.4084\/mjhid.2015.040","volume":"7","author":"S Esposito","year":"2015","unstructured":"Esposito S, Gioia R, De Simone G, Noviello S, Lombardi D, Di Crescenzo VG, Filippelli A, Rega MR, Massari A, Elberti MG, Grisi L, Boccia G, De Caro F, Leone S (2015) Bacterial epidemiology and antimicrobial resistance in the surgery wards of a large teaching hospital in southern Italy. Mediterr J Hematol Infect Dis 7:e2015040","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"3533_CR10","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1179\/joc.2003.15.6.568","volume":"15","author":"S Esposito","year":"2003","unstructured":"Esposito S, Capuano A, Noviello S, Mazzeo F, Ianniello F, Filippelli A, Rossi F, Leone S (2003) Modification of patients\u2019 endogenous bacterial flora during hospitalization in a large teaching hospital in Naples. J Chemother 15:568\u2013573","journal-title":"J Chemother"},{"key":"3533_CR11","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1093\/jac\/dkp005","volume":"63","author":"P Montravers","year":"2009","unstructured":"Montravers P, Lepape A, Dubreuil L, Gauzit R, Pean Y, Benchimol D, Dupont H (2009) Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study. J Antimicrob Chemother 63:785\u2013794","journal-title":"J Antimicrob Chemother"},{"key":"3533_CR12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/MEG.0000000000001057","volume":"30","author":"M Fiore","year":"2018","unstructured":"Fiore M, Gentile I, Maraolo AE, Leone S, Simeon V, Chiodini P, Pace MC, Gustot T, Taccone FS (2018) Are third-generation cephalosporins still the empirical antibiotic treatment of community-acquired spontaneous bacterial peritonitis? A systematic review and meta-analysis. Eur J Gastroenterol Hepatol 30:329\u2013336","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3533_CR13","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.2147\/TCRM.S144262","volume":"13","author":"M Fiore","year":"2017","unstructured":"Fiore M, Maraolo AE, Leone S, Gentile I, Cuomo A, Schiavone V, Bimonte S, Pace MC, Cascella M (2017) Spontaneous peritonitis in critically ill cirrhotic patients: a diagnostic algorithm for clinicians and future perspectives. Ther Clin Risk Manag 13:1409\u20131414","journal-title":"Ther Clin Risk Manag"},{"key":"3533_CR14","doi-asserted-by":"publisher","first-page":"3606","DOI":"10.1128\/AAC.05186-14","volume":"59","author":"SH Lob","year":"2015","unstructured":"Lob SH, Kazmierczak KM, Badal RE, Hackel MA, Bouchillon SK, Biedenbach DJ, Sahm DF (2015) Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013. Antimicrob Agents Chemother 59:3606\u20133610","journal-title":"Antimicrob Agents Chemother"},{"key":"3533_CR15","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ijantimicag.2006.10.017","volume":"29","author":"S Esposito","year":"2007","unstructured":"Esposito S, Leone S (2007) Antimicrobial treatment for intensive care unit (ICU) infections including the role of the infectious disease specialist. Int J Antimicrob Agents 29:494\u2013500","journal-title":"Int J Antimicrob Agents"},{"key":"3533_CR16","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1586\/14787210.3.4.593","volume":"3","author":"S Esposito","year":"2005","unstructured":"Esposito S, Leone S, Noviello S (2005) Management of severe bacterial infections. Expert Rev Anti-Infect Ther 3:593\u2013600","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"3533_CR17","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.cmi.2017.09.001","volume":"23","author":"H Wright","year":"2017","unstructured":"Wright H, Bonomo RA, Paterson DL (2017) New agents for the treatment of infections with gram-negative bacteria: restoring the miracle or false dawn? Clin Microbiol Infect 23:704\u2013712","journal-title":"Clin Microbiol Infect"},{"key":"3533_CR18","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s40265-015-0524-5","volume":"76","author":"LJ Scott","year":"2016","unstructured":"Scott LJ (2016) Ceftolozane\/tazobactam: a review in complicated intra-abdominal and urinary tract infections. Drugs 76:231\u2013242","journal-title":"Drugs"},{"key":"3533_CR19","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.1128\/AAC.00049-14","volume":"58","author":"C Lucasti","year":"2014","unstructured":"Lucasti C, Hershberger E, Miller B, Yankelev S, Steenbergen J, Friedland I, Solomkin J (2014) Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections. Antimicrob Agents Chemother 58:5350\u20135357","journal-title":"Antimicrob Agents Chemother"},{"key":"3533_CR20","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/cid\/civ097","volume":"60","author":"J Solomkin","year":"2015","unstructured":"Solomkin J, Hershberger E, Miller B, Popejoy M, Friedland I, Steenbergen J, Yoon M, Collins S, Yuan G, Barie PS, Eckmann C (2015) Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis 60:1462\u20131471","journal-title":"Clin Infect Dis"},{"key":"3533_CR21","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1093\/jac\/dkw374","volume":"2","author":"MW Popejoy","year":"2017","unstructured":"Popejoy MW, Paterson DL, Cloutier D, Huntington JA, Miller B, Bliss CA, Steenbergen JN, Hershberger E, Umeh O, Kaye KS (2017) Efficacy of ceftolozane\/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of phase 3 clinical trials. J Antimicrob Chemother 2:268\u2013272","journal-title":"J Antimicrob Chemother"},{"key":"3533_CR22","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ijantimicag.2015.05.003","volume":"46","author":"JL Liscio","year":"2015","unstructured":"Liscio JL, Mahoney MV, Hirsch EB (2015) Ceftolozane\/tazobactam and ceftazidime\/avibactam: two novel \u03b2-lactam\/\u03b2-lactamase inhibitor combination agents for the treatment of resistant gram-negative bacterial infections. Int J Antimicrob Agents 46:266\u2013271","journal-title":"Int J Antimicrob Agents"},{"key":"3533_CR23","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1093\/jac\/dks523","volume":"68","author":"C Lucasti","year":"2013","unstructured":"Lucasti C, Popescu I, Ramesh MK, Lipka J, Sable C (2013) Comparative study of the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial. J Antimicrob Chemother 68:1183\u20131192","journal-title":"J Antimicrob Chemother"},{"key":"3533_CR24","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/cid\/ciw133","volume":"62","author":"JE Mazuski","year":"2016","unstructured":"Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D, Llorens L, Newell P, Pachl J (2016) Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis 62:1380\u20131389","journal-title":"Clin Infect Dis"},{"key":"3533_CR25","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ijantimicag.2017.01.010","volume":"49","author":"X Qin","year":"2017","unstructured":"Qin X, Tran BG, Kim MJ, Wang L, Nguyen DA, Chen Q, Song J, Laud PJ, Stone GG, Chow JW (2017) A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia. Int J Antimicrob Agents 49:579\u2013588","journal-title":"Int J Antimicrob Agents"},{"key":"3533_CR26","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1093\/jac\/dky204","volume":"73","author":"GG Stone","year":"2018","unstructured":"Stone GG, Newell P, Gasink LB, Broadhurst H, Wardman A, Yates K, Chen Z, Song J, Chow JW (2018) Clinical activity of ceftazidime\/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime\/avibactam phase III clinical trial programme. J Antimicrob Chemother 73:2519\u20132523","journal-title":"J Antimicrob Chemother"},{"key":"3533_CR27","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.diagmicrobio.2018.08.007","volume":"93","author":"Y Mo","year":"2019","unstructured":"Mo Y, Lorenzo M, Farghaly S, Kaur K, Housman ST (2019) What\u2019s new in the treatment of multidrug-resistant gram-negative infections? Diagn Microbiol Infect Dis 93:171\u2013181","journal-title":"Diagn Microbiol Infect Dis"},{"key":"3533_CR28","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.2147\/IDR.S150447","volume":"11","author":"LA Petty","year":"2018","unstructured":"Petty LA, Henig O, Patel TS, Pogue JM, Kaye KS (2018) Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae. Infect Drug Resist 11:1461\u20131472","journal-title":"Infect Drug Resist"},{"key":"3533_CR29","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","volume":"7","author":"RG Wunderink","year":"2018","unstructured":"Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, Mathers AJ, Bassetti M, Vazquez J, Cornely OA, Solomkin J, Bhowmick T, Bishara J, Daikos GL, Felton T, Furst MJL, Kwak EJ, Menichetti F, Oren I, Alexander EL, Griffith D, Lomovskaya O, Loutit J, Zhang S, Dudley MN, Kaye KS (2018) Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with Carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial. Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect Dis Ther 7:439\u2013455","journal-title":"Infect Dis Ther"},{"key":"3533_CR30","doi-asserted-by":"publisher","first-page":"6234","DOI":"10.1128\/AAC.00633-16","volume":"60","author":"C Lucasti","year":"2016","unstructured":"Lucasti C, Vasile L, Sandesc D, Venskutonis D, McLeroth P, Lala M, Rizk ML, Brown ML, Losada MC, Pedley A, Kartsonis NA, Paschke A (2016) Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection. Antimicrob Agents Chemother 60:6234\u20136243","journal-title":"Antimicrob Agents Chemother"},{"key":"3533_CR31","unstructured":"Motsch J, de Oliveira C, Stus V, Koksal I, Lyulko O, Boucher HW, Kaye KS, File T, Brown M, Khan I, Du J, Joeng HK, Tipping R, Aggrey A, Young K, Kartsonis N, Butterton J, Paschke A (2018) A multicenter, randomized, double-blind, comparator controlled trial comparing the efficacy and safety of imipenem\/relebactam versus colistin plus imipenem in patients with imipenem-non-susceptible bacterial infections. 28th European Congress of Clinical Microbiology and Infectious Diseases. O0427. April, 21\u201324"},{"key":"3533_CR32","first-page":"e01856","volume":"62","author":"HS Sader","year":"2017","unstructured":"Sader HS, Mendes RE, Pfaller MA, Shortridge D, Flamm RK, Castanheira M (2017) Antimicrobial activities of aztreonam-avibactam and comparator agents against contemporary (2016) clinical Enterobacteriaceae isolates. Antimicrob Agents Chemother 62:e01856\u2013e01817","journal-title":"Antimicrob Agents Chemother"},{"key":"3533_CR33","unstructured":"Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) \u00b1 Metronidazole (MTZ) Versus Meropenem (MER) \u00b1 Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03329092 ClinicalTrials.gov identifier: NCT03329092. Accessed 28 November 2018"},{"key":"3533_CR34","first-page":"pii: e01968","volume":"62","author":"MA Hackel","year":"2018","unstructured":"Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF (2018) In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of gram-negative bacilli collected worldwide in 2014 to 2016. Antimicrob Agents Chemother 62:pii: e01968\u2013pii: e01917","journal-title":"Antimicrob Agents Chemother"},{"key":"3533_CR35","unstructured":"Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02714595 ClinicalTrials.gov Identifier: NCT02714595. Accessed 28 November 2018"},{"key":"3533_CR36","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1128\/AAC.00572-10","volume":"54","author":"JB Aggen","year":"2010","unstructured":"Aggen JB, Armstrong ES, Goldblum AA, Dozzo P, Linsell MS, Gliedt MJ, Hildebrandt DJ, Feeney LA, Kubo A, Matias RD, Lopez S, Gomez M, Wlasichuk KB, Diokno R, Miller GH, Moser HE (2010) Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob Agents Chemother 54:4636\u20134642","journal-title":"Antimicrob Agents Chemother"},{"key":"3533_CR37","first-page":"3346","volume":"73","author":"M Castanheira","year":"2018","unstructured":"Castanheira M, Deshpande LM, Woosley LN, Serio AW, Krause KM, Flamm RK (2018) Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms. J Antimicrob Chemother 73:3346\u20133354","journal-title":"J Antimicrob Chemother"},{"key":"3533_CR38","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.diagmicrobio.2018.07.006","volume":"92","author":"M Thwaites","year":"2018","unstructured":"Thwaites M, Hall D, Stoneburner A, Shinabarger D, Serio AW, Krause KM, Marra A, Pillar C (2018) Activity of plazomicin in combination with other antibiotics against multidrug-resistant Enterobacteriaceae. Diagn Microbiol Infect Dis 92:338\u2013345","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"Suppl 1","key":"3533_CR39","doi-asserted-by":"publisher","first-page":"S531","DOI":"10.1093\/ofid\/ofx163.1383","volume":"4","author":"JA Mckinnell","year":"2017","unstructured":"Mckinnell JA, Connolly LE, Pushkin R, Jubb AM, O\u2019Keeffe B, Serio AW, Smith A, Gall J, Riddle V, Krause KM, Pogue JM (2017) Improved outcomes with plazomicin (PLZ) compared with colistin (CST) in patients with bloodstream infections (BSI) caused by carbapenem-resistant Enterobacteriaceae (CRE): results from the CARE study. Open Forum Infect Dis 4(Suppl 1):S531","journal-title":"Open Forum Infect Dis"},{"key":"3533_CR40","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.diagmicrobio.2017.12.013","volume":"91","author":"GG Zhanel","year":"2018","unstructured":"Zhanel GG, Baxter MR, Adam HJ, Sutcliffe J, Karlowsky JA (2018) In vitro activity of eravacycline against 2213 gram-negative and 2424 gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015. Diagn Microbiol Infect Dis 91:55\u201362","journal-title":"Diagn Microbiol Infect Dis"},{"key":"3533_CR41","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1179\/joc.2008.20.5.577","volume":"20","author":"S Noviello","year":"2008","unstructured":"Noviello S, Ianniello F, Leone S, Fiore M, Esposito S (2008) In vitro activity of tigecycline: MICs, MBCs, time-kill curves and post-antibiotic effect. J Chemother 20:577\u2013580","journal-title":"J Chemother"},{"key":"3533_CR42","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1128\/AAC.01614-13","volume":"58","author":"JS Solomkin","year":"2014","unstructured":"Solomkin JS, Ramesh MK, Cesnauskas G, Novikovs N, Stefanova P, Sutcliffe JA, Walpole SM, Horn PT (2014) Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections. Antimicrob Agents Chemother 58:1847\u20131854","journal-title":"Antimicrob Agents Chemother"},{"key":"3533_CR43","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","volume":"152","author":"J Solomkin","year":"2017","unstructured":"Solomkin J, Evans D, Slepavicius A, Lee P, Marsh A, Tsai L, Sutcliffe JA, Horn P (2017) Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial. JAMA Surg 152:224\u2013232","journal-title":"JAMA Surg"},{"key":"3533_CR44","unstructured":"Horn P, Tsai L, Solomkin J, Evans D, Gardovskis J (2018) Results of IGNITE4: a phase 3 study to evaluate the efficacy and safety of eravacycline versus meropenem in complicated intra-abdominal infection. 28th European Congress of Clinical Microbiology and Infectious Diseases. O0421. April, 21\u201324"},{"key":"3533_CR45","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ijantimicag.2013.06.002","volume":"42","author":"S Leone","year":"2013","unstructured":"Leone S, Rossi M, Bisi L, Gori A, Esposito S (2013) Antimicrobial therapy duration: a major matter in the management of severe infections. Int J Antimicrob Agents 42:287\u2013288","journal-title":"Int J Antimicrob Agents"},{"key":"3533_CR46","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ijantimicag.2011.06.003","volume":"38","author":"S Leone","year":"2011","unstructured":"Leone S, Stefani S, Venditti M, Grossi P, Colizza S, De Gasperi A, Scaglione F, Sganga G, Esposito S (2011) Intra-abdominal infections: model of antibiotic stewardship in an era with limited antimicrobial options. Int J Antimicrob Agents 38:271\u2013272","journal-title":"Int J Antimicrob Agents"},{"key":"3533_CR47","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1080\/14656566.2018.1512584","volume":"19","author":"M Fiore","year":"2018","unstructured":"Fiore M, Taccone FS, Leone S (2018) Choosing the appropriate pharmacotherapy for multidrug-resistant gram positive infections. Expert Opin Pharmacother 19:1517\u20131521","journal-title":"Expert Opin Pharmacother"},{"key":"3533_CR48","doi-asserted-by":"publisher","unstructured":"Leone S, Cascella M, Pezone I, Fiore M (2019) New antibiotics for the treatment of serious infections in intensive care unit patients. Curr Med Res Opin. https:\/\/doi.org\/10.1080\/03007995.2019.1583025","DOI":"10.1080\/03007995.2019.1583025"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-019-03533-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-019-03533-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-019-03533-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T22:26:04Z","timestamp":1574375164000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-019-03533-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,23]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["3533"],"URL":"https:\/\/doi.org\/10.1007\/s10096-019-03533-y","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,23]]},"assertion":[{"value":"14 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}